Drugs / Recombinant Human Lactoferrin
Recombinant Human Lactoferrin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02968992 | Aug 2017 → Feb 2019 | cognitive disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00095186 | Sep 2004 → Mar 2007 | renal cell carcinoma | Agennix | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00377078 | Oct 2005 → Oct 2007 | Clostridium difficile colitis | Johns Hopkins University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Lactoferrin | “Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be...” NCT02968992 ↗ |
| Known as | Lactoferrin (human) | “Product to be tested: Lactoferrin (human) derived from rice.” NCT00377078 ↗ |
| Known as | rhLactoferrin | “Drug: rhLactoferrin” NCT02968992 ↗ |
| Known as | rhLF | “The purpose of this study is to investigate how recombinant human lactoferrin (rhLF) which is a partially iron saturated form of lactoferrin produced and purified from rice...” NCT02968992 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human lactoferrin” NCT00095186 ↗ |
| Route | Oral | “will be administered orally” NCT00095186 ↗ |